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2 Summary
Acrylamido-quinazolines substituted at the 6-position bind irreversibly to the intracellular
ATP binding domain of the epidermal growth factor receptor (EGFR).  A general route was
developed for preparing 6-substituted-4-anilinoquinazolines from [18F]fluoroanilines for
evaluation as EGFR targeting agents with PET.  By a cyclization reaction, 2-[18F]fluoroaniline
was reacted with N'-(2-cyano-4-nitrophenyl)-N,N-dimethylimidoformamide to produce 6-
nitro-4-(2-[18F]fluoroanilino)quinazoline in 27.5% decay-corrected radiochemical yield.  Acid
mediated tin chloride reduction of the nitro group was achieved in 5 min (80% conversion)
and subsequent acylation wi th  acrylic acid  gave 6-acrylamido-4-(2-
[18F]fluoroanilino)quinazoline in 8.5% decay-corrected radiochemical yield, from starting
fluoride, in less than 2 hours.
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3Introduction
The epidermal growth factor receptor (EGFR) is a member of the ErbB family of
receptor tyrosine kinases (tk) and is often overexpressed in a variety of tumors. Inhibition of
the EGFR-tk is a focal point in therapeutic development and considered to be an important
target for cancer therapy.1 Recently, 6-acrylamido-4-anilino-quinazolines have been
developed as a class of therapeutic agents that bind irreversibly to the intracellular ATP
binding domain of the EGFR-tk and inhibit downstream cell signaling events.2,3  Radiolabeled
EGFR-tk probes may be instrumental in understanding tumor biology or as tools for drug
development.
Mishani and coworkers4-7 have synthesized and evaluated 6-substituted-4-
haloanilinoquinazolines labeled with carbon-11 (half-life = 20.4 min) as novel irreversible
positron emission tomography (PET) probes for EGFR-tk. These tracers have been explored
to overcome the ATP competitive binding that may have interfered with the retention of the
carbon-11 labeled reversible probes.4,7  As a longer-lived alternative to the carbon-11 probes,
we report herein the synthesis of 6-acrylamido-4-(2-[18F]fluoroanilino)quinazoline ([18F]7) as
a potential probe for EGFR-tk. The increased tracer lifetime (fluorine-18 half-life = 109.7
min) may provide a better match to the pharmacokinetics and EGFR turnover.
Our synthetic strategy involves the following steps: (1) preparation of a radiolabeled
aniline;  (2) ring closure of N'-(2-cyano-4-nitrophenyl)-N,N-dimethylimidoformamide, 4, with
the labeled aniline to form 6-nitro-4-anilinoquinazoline;8 (3) reduction of the nitro group to
form 6-amino-4-anilinoquinazoline, a key intermediate for several labeled analogs; and (4)
acylation of the amine with acrylic acid.8,9  This strategy may be extended to provide a series
of labeled 6-substituted-4-anilinoquinazolines.
Results and discussion
Scheme 1 shows the synthetic route to [18F]7 . Fluorine-18 labeled 2-fluoroaniline
4hydrochloride ([1 8F]3) was selected for coupling to 4 because it is efficiently prepared10 and
potentially possesses suitable metabolic properties when coupled to quinazolines.11,12
Cyclization provides 6-nitro-4-(2-[18F]fluoroanilino)quinazoline ([18F]5), incorporating the
labeled 4-anilino moiety in a single step.  Compound [18F]5 was obtained (after HPLC
purification) in 27.5% decay-corrected radiochemical yield, relative to the initial 18F-fluoride
activity.  Acid mediated nitro group reduction of [18F]5 to [18F]6 with tin chloride was
accomplished in 5 min with 80% conversion.  Subsequent acylation with acrylic acid followed
by HPLC purification provided chemically and radiochemically pure [18F]7 (> 95%).  The
overall radiochemical yield was 8.5% from starting fluoride in less than 120 minutes. The
measured specific activity at the end of synthesis was 12.1 GBq/mmol. The corresponding
fluorine-19 analogs, compounds 5-7, were prepared by the same route (Scheme 1) and were
characterized by 1H NMR spectroscopy and electron impact mass spectrometry.  The
identities of [18F]5 - [18F]7 were confirmed by comparison of the HPLC retention times and
co-injection with unlabeled 5 - 7.
We have recently described the optimized synthesis of 2-, 3- and 4-
[18F]fluoroanilines.10  As the [18F]fluoroaniline isomers are similarly prepared, one could
easily substitute the 3- and 4-[18F]fluoroanilines in the current approach. Likewise, one could
envision extending the series with radiobromo- or radioiodo-anilines. Additionally, elaboration
in the 6 position such as the acetamido analogs reported by Mishani and coworkers9 expands
the series of potential EGFR-tk probes. Thus, the chosen synthetic approach permits the
preparation of a variety of labeled quinazolines compounds for assessment as biologic probes.
5Experimental Section
Materials 
Absolute EtOH USP (Aaper), NaBH4 (Spectrum), HPLC grade MeOH (Burdick & Jackson),
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI•HCl; Pierce), stannous
chloride dihydrate (Mallinckrodt) and [18O]H2O (Rotem Industries Ltd., Israel, > 94.1 atom
%) were used without further purification.  All other reagents were purchased from Aldrich
and were used without further purification, with the exception of 1,2-dinitrobenzene (Aldrich,
> 99%), which was recrystallized from EtOAc prior to use.
Standard techniques  
Preparative HPLC was performed at room temperature using a Beckman Ultrasphere C-18 5-
µm column (250 mm x 10 mm) with 65 : 35 (v/v) CH3OH : H2O (1% Et3N in H2O adjusted to
pH = 7.4 with H3PO4) as the mobile phase.  A flow rate of 6 mL min
-1 was used (pump:
Waters model 590) and the eluent was monitored for UV absorbance at 254 nm (detector:
Linear UV-106) and radioactivity (detector: Carroll and Ramsey Associates Model 105S).
Analytical HPLC was performed with the same solvent system on a Phenomenex Hypersil
C18 (ODS) 5-µm column (250 mm x 4.6 mm) with a flow rate of 1 mL min-1 and the eluent
was monitored for UV absorbance at 254 nm (detector: Linear UVIS 200).  The 1H NMR
spectra were recorded in CD3OD on a Bruker AV-300 (300 MHz) spectrometer at 30 
oC.
The mass spectrometry analyses were conducted using a VG ProSpec spectrometer equipped
with an electron impact (EI) source operated at 70 eV.
No-carrier-added 18F-fluoride was produced by 10 MeV proton irradiation of 30% enriched
[18O]H2O at low pressure in a silver target by the 
18O(p,n)18F nuclear reaction on the
Biomedical Isotope Facility CTI RDS 111-DV01 cyclotron.  The [18O]H2O/
18F- (100 – 450
µL) was transferred into a conical glass vial containing Kryptofix 222 (5 mg, 13.2 µmol),
6K2CO3 (0.5 mg, 3.62 µmol) in 500 µL of CH3CN.  The water was removed by azeotropic
distillation with anhydrous CH3CN (1 mL) at 100 
oC in vacuo, under a stream of nitrogen.
The azeotropic drying process was repeated.
Radiochemistry:
6-nitro-4-(2-[18F]fluoroanilino)quinazoline ([18F]5)
Fluorine-18 labeled 2-fluoroaniline hydrochloride ([1 8F]3) was prepared as previously
described10 and subsequently reacted with 400 µL of a saturated solution of N'-(2-cyano-4-
nitrophenyl)-N,N-dimethylimidoformamide (1 mL of glacial AcOH added to 50 mg of 4) at
100 oC for 20 min to provide 6-nitro-4-(2-[18F]fluoroanilino)quinazoline ([18F]5).  The
reaction mixture was made basic with NaOH (1 mL, 1 M) and diluted to 4 mL with H2O.
The mixture was passed sequentially through a cartridge loaded with Celite® 521 filtering
agent (Aldrich), an activated C18 solid phase extraction cartridge (Sep-Pak®, Waters) and a 45
µm nylon disc-filter (Acrodisc Premium, Pall), connected in series, and rinsed with 4 mL
H2O.  [
18F]5 was eluted with MeOH (3 mL) into a separate vial, diluted with 1 mL of H2O
and injected onto the semi-preparative HPLC system.  [18F]5 (tR = 6.5 min) was well
separated from excess 4 (tR = 4.0 min).  [
18F]5 was identified by the semi-preparative (tR =
6.5 min) and analytical (tR = 6.9 min) HPLC retention times and co-injection with authentic
compound 5.  The HPLC peak containing [18F]5 was collected, diluted to 20 mL with H2O,
concentrated on a C18 cartridge and eluted with 2.5 mL EtOH.  Isolated [18F]5 was obtained
in 27.5 ± 1.5% (n = 3) decay-corrected radiochemical  yield, relative to the initial 18F-fluoride
activity.
6-amino-4-(2-[18F]fluoroanilino)quinazoline ([18F]6)
7The ethanolic solution of [18F]5 was added to a vial containing SnCl2•2H2O (8 mg, 35 µmol),
followed by the addition of 20 µL conc. HCl.  The reaction vessel was sealed with a Teflon
lined screw cap and heated at 100 oC for 5 min to yield 6-amino-4-(2-
[18F]fluoroanilino)quinazoline ([18F]6), which was used without further purification.  In
separate experiments, semi-preparative HPLC was used to determine the reduction efficiency.
The conversion from [18F]5 to [18F]6 was found to be 80%.  [18F]6 was identified by the
semi-preparative (tR = 3.2 min) and analytical (tR = 4.1 min) HPLC retention times and co-
injection with authentic compound 6.
6-acrylamido-4-(2-[18F]fluoroanilino)quinazoline ([18F]7)
The ethanolic reaction mixture containing [18F]6 was evaporated to dryness at 100 oC in
vacuo.  To the dry residue, a DMF solution (300 µL) containing EDCI•HCl (6 mg, 31 µmol),
followed by pyridine (50 µL) and acrylic acid (10 µL of a 20% acrylic acid solution in DMF,
0.03 µmol) were added.  The reaction vessel was sealed with a Teflon lined screw cap and the
acylation proceeded at room temperature for 5 min.  The reaction mixture was diluted to 5 mL
with H2O and loaded onto a C18 cartridge, then rinsed with an additional 2 mL H2O.  [
18F]7
was eluted with 3 mL MeOH into a separate vial, diluted with 1 mL H2O and injected onto
the semi-preparative HPLC system.  The collected fraction containing compound [18F]7 was
diluted to 20 mL with H2O, concentrated onto a C-18 cartridge and extracted into a test tube
with methanol.  The methanol was evaporated at 100 oC in vacuo and [18F]7 was obtained in
8.5 ± 2% decay-corrected radiochemical yield (n = 3) in less than 2 hours with greater than
95% chemical and radiochemical purity as measured by analytical HPLC.  [18F]7  was
identified by the semi-preparative (tR = 5.5 min) and analytical (tR = 6.0 min) HPLC retention
times and co-injection with authentic compound 7. [18F]7 is resolubilized by heating with 20
8µL of EtOH at 100 oC for 10 seconds, followed by the addition of saline or aqueous buffer
(e.g. Krebs-Henseleit buffer) to achieve the desired final concentration. The specific activity
was determined by analytical HPLC.
Syntheses of non-radioactive standard compounds:
6-nitro-4-(2-fluoroanilino)quinazoline (5)
N'-(2-cyano-4-nitrophenyl)-N,N-dimethylimidoformamide,8 4, (2.4 g, 11.0 mmol) and
2-fluoroaniline (1.41g, 13.0 mol) were stirred in AcOH (100 mL) at reflux for 2 h.  The
resulting solid was filtered hot and washed with ether, followed by drying at 50 °C in vacuo
to give 1.86 g (60%) of 5  as a yellow solid.  1H NMR spectrum, δ  (ppm, relative to
TMS): 9.58 (bs, 1H ), 8.61 (s, 1H), 8.57 (dd, J = 2.5 Hz, J = 9.2 Hz, 1H), 7.94 (d, J = 9.2
Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 7.25 - 7.37 (m, 3H); MS (EI) m/z 284.
6-amino-4-(2-fluoroanilino)quinazoline (6)
A mixture of 6-nitro-4-(2-fluoroanilino)quinazoline, 5, (1.2 g, 4.33 mmol) was stirred in
EtOH (7.5 mL) with Fe (1.2 g, 21.5 mmol) and AcOH (2 mL).  Upon heating to reflux,
additional EtOH (2 mL) and AcOH (0.5 mL) were added and heating was continued for 3 h.
After cooling the mixture to room temperature, the solution was filtered and the residue
washed with H2O (20 mL), then MeOH (3 x 20 mL).  The combined filtrates were neutralized
with NH4OH and extracted with CHCl3.  The organic layer was dried (Na2SO4), decolorized
with charcoal, and the solvent was removed in vacuo.  The residue was purified b y
chromatography (10% MeOH-CHCl3, silica gel) to provide 0.5 g (45%) of 6, a yellow solid.
1H NMR spectrum, δ (ppm, relative to TMS): 9.25 (bs, 1H), 8.19 (bs, 1H), 7.56 (t, J = 7.19
Hz, 1H), 7.51 (d, J = 8.7 Hz, 1H), 7.20 - 7.28 (m, 4H); MS (EI) m/z 254.
6-acrylamido-4-(2-fluoroanilino)quinazoline (7)
Acrylic acid (91 µL, 1.1 mmol) was added dropwise into an ice-cold solution of 6-
amino-4-(2-fluoroanilino)quinazoline , 6, (0.127g, 0.5 mmol) in pyridine (0.5 mL) and DMF
9(4 mL).  After a few minutes EDCI·HCl (0.239 g, 1.25 mmol) was added.  The reaction was
warmed to room temperature and stirred for 1 h.  The solvent was removed in vacuo and the
residue was purified by chromatography (5% MeOH-CHCl3, silica gel) to  provide 0.2 g
(8.5%) of 7.  1H NMR spectrum, δ (ppm, relative to TMS):  8.75 (d, J = 2.2 Hz, 1H), 8.39
(s, 1H), 7.84 (dd, J = 2.2 Hz, J = 8.9 Hz, 1H), 7.75 (d, J = 8.9 Hz, 1H), 7.67 (dt, J= 1.8 Hz, J
= 7.8 Hz), 7.35 – 7.20 (m, 3H), 6.47 (d, J = 3.8 Hz, 1H), 6.46 (d, J = 8.1 Hz, 1H), 5.83 (dd, J
= 3.8 Hz, J = 8.1 Hz, 3H); MS (EI) m/z 308.
Conclusions
The first prospective fluorine-18 labeled irreversibly-binding EGFR-tk tracer, 6-
acrylamido-4-([18F]2-fluoroanilino)quinazolines, ([18F]7), has been prepared.  The synthetic
strategy reported herein may be applied to develop a series of labeled compounds through
acylation of the amine at position 6 and/or coupling with substituted anilines for assessment
as EGFR-tk probes.
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Scheme 1.  Reagents: (i) K18F/K222, DMSO, 130 
oC, 5 min; (ii) NaBH4/Pd-C, rt, 5 min; (iii)
HCl; (iv) HOAc, 100 oC, 20 min; (v) NaOH; (vi) SnCl2•2H2O, HCl, 100 
oC, 5 min; (vii)
acrylic acid, EDCI•HCl, pyridine, DMF, rt, 5 min.
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